ScienceEnzyme foams morer active and stableResearchers at the Karlsruhe Institute of Technology (KIT) have transformed enzymes into a new form: as foams, the biocatalysts prove to be extremely stable and active. more ➔
FundingBavarian Nordic A/S bags US$120m for small...Bavarian Nordic A/S will get US$120m from a contract for the manufacturing of smallpox and mpox vaccine from the US government. more ➔
FundingPureTech Health gets US$11.4m to advance L...LSE-listed PureTech Health plc hat been granted p to US$11.4m from U.S. Department of Defense to advance LYT-300 to treat Fragile X-associated tremor/ataxia syndrome. more ➔
MSNeuraxpharm pays US$650m for MS drug comme...TG Therapeutics will receive US$140m upfront from German Neuraxpharm for Ex-US commercialisation rights of its deglycosylated anti-CD20 antibody ublituximab-xiiy. more ➔
DealMithra Pharmaceuticals SA in €17m licenc...Mithra and Searchlight Pharma have inked a licensing deal for Donesta commercialisation in Canada. more ➔
ScienceBacterial-fungal consortium denitrifies wa...A German-Chinese reasearch consortium has identified a highly active denitrifying microbial consortium that denitrifies wastewater by almost 100%. more ➔
CollaborationRetinopathy: Golgi and Breye join forcesMilan-based biotech incubator Golgi Neurosciences is teaming up with Danish biopharma Breye Therapeutics to develop the P2X7 receptor antagonist programme for the treatment of retinal disorders. more ➔
FinancingNK cell therapy company NK:IO raises seed...British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m. more ➔
DealAlnylam in US$2.8bn biobucks deal with Roc...siRNA specialist Alnylam Pharmaceuticals Roche has received US$310m upfront from Swiss Roche AG for the ex-US commercialisation rights of zilebesiran, an new antihypertensive. T more ➔
IPResistance blocker of immune checkpoint in...The EPO has granted a patent to Domain Therapeutics Phase I candidate DT-9081 designed to reverse PGE2-mediated immunosuppression used by tumours to bypass the immune system. more ➔
